Tofacitinib citrate
Cat. No.：YN340233
CAS No. ：540737-29-9
| 产品名称: | Tofacitinib citrate |
| CAS No.: | 540737-29-9 |
| Chemical Name: | (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4R-ylamino)-β-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate |
| Synonyms: | 枸橼酸托法替尼; Tasocitinib citrate; CP-690550 citrate |
| 分子量: | 504.49 |
| 分子式: | C₂₂H₂₈N₆O₈ |
| SMILES: | O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Tofacitinib citrate是JAK3/2/1抑制剂，IC50分别为1，20 和 112 nM。Tofacitinib citrate 具有抗菌，抗真菌和抗病毒活性。 |
| IC50和靶点: | [{name:"JAK3:1 nM (IC50)"},{name: "JAK2:20 nM (IC50)"},{name: "JAK1:112 nM (IC50)"},{name: "Rock-II:3400 nM (IC50)"},{name: "Lck:3870 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Haan, C., Rolvering, C., Raulf, F., et al.Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptorsChem. Biol.18(3),314-323(2011)
Changelian, P.S., Flanagan, M.E., Ball, D.J., et al.Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitorScience302(5646),875-878(2003)
Flanagan, M.E., Blumenkopf, T.A., Brissette, W.H., et al.Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejectionJ. Med. Chem.53(24),8468-8484(2010)
Cutolo, M.The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: Latest findings and clinical potentialTher. Adv. Musculoskelet. Dis.5(1),3-11(2013)
Sandborn, W.J., Ghosh, S., Panes, J., et al.Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitisN. Engl. J. Med.367(7),616-624(2012)
